

Special Issue

Vaccine Related Immune Responses

Message from the Guest Editors

The use of vaccination to prevent infectious diseases was described long before establishing the fundamental dogmas of the immune system. Vaccines activate the immune system and generate memory T and B lymphocytes that "remember" the disease-causing agents. Upon encountering these pathogens later, the immune system will mount a rapid and robust immune response to antigens it has previously experienced, thereby preventing disease or reducing its severity. For most vaccines, more than one dose is necessary to provide long-lasting protection. Since the advent of recombinant DNA technology, vaccines have become the mainstay of protection against several infectious and non-infectious diseases. How a vaccine stimulates the immune system depends on many factors, such as the nature of the antigens, the route of administration, and the adjuvant present in the vaccines. This Special Issue aims to collect recent research related to vaccine-related immune responses, including recent advances in mRNA vaccines. We hope to provide a broad overview of how different vaccines work and help understand some new techniques and their utilization in vaccinology.

Guest Editors

Dr. Abhisek Bhattacharya

National Cancer Institute (NCI), National Institutes of Health (NIH),
Bethesda, MD 20814, USA

Dr. Zhongmei Zhang

National Cancer Institute (NCI), Bethesda, MD, USA

Deadline for manuscript submissions

closed (10 June 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/104052

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).